Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01333878|
Recruitment Status : Completed
First Posted : April 12, 2011
Last Update Posted : April 17, 2014
|Condition or disease||Intervention/treatment||Phase|
|Rheumatoid Arthritis||Biological: Subcutaneous Abatacept||Phase 2 Phase 3|
This is an open-label study of the efficacy of subcutaneous (SC) Abatacept to inhibit progression of structural joint damage in patients with active rheumatoid arthritis (RA) receiving MTX and have inadequate disease control (defined as an ESR based DAS28 ≥ 3.2 AND ≥ 6 swollen and ≥ 6 tender joints). The study consists of a screening period (Days -21 to -7), a baseline visit (Days -20 to -1), and a treatment Period (open label Abatacept 125 mg SC for 24 weeks). All the visits may occur at the indicated week +/- 2 days. The last efficacy assessments are to be conducted at Week 24 and subjects are to be contacted by telephone for a safety follow-up 2 months after the final study agent has been administered.
The maximum length of the study is 35 weeks, which includes the 2-week screening period, 1-week baseline period, 24-week open label treatment, and 8-week follow-up period. Eligible subjects are to continue their current MTX treatment regimen, a stable dose of at least 15mg/week, during the entire length of the study (24 weeks). At Day 0, patients who meet inclusion criteria, will be dosed from Day 0 to Week 24 with Abatacept 125 mg SC injection.
Subjects are to self-administer SC study agent at Weeks 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, and 23 and are not required to return to the study site at these weeks. All other visits, SC study agent is to be administered while the subject is at the study site.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label, Pilot Trial to Assess the Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage Determined by Low Field Extremity MRI (eMRI) and X-ray|
|Study Start Date :||March 2011|
|Actual Primary Completion Date :||November 2013|
|Actual Study Completion Date :||January 2014|
Experimental: Open-Label Subcutaneous Abatacept
Open-Label Subcutaneous Abatacept
Biological: Subcutaneous Abatacept
Subcutaneous Abatacept 125 mg once weekly for 6 months
- Inhibition & progression of structural damage [ Time Frame: 6 months ]Assess inhibition & progression of structural damage in MTX inadequate responders with moderate to severe active RA on SC Abatacept plus MTX, utilizing eMRI and X-ray at baseline, eMRI at Week 12, and eMRI and X-ray final assessment at week 24.
- Improvement in ESR-based DAS28 [ Time Frame: 6 months ]Assess improvement in ESR-based DAS28, physician global assessment, and improvement in HAQ score
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01333878
|United States, California|
|Orrin M. Troum, MD and Medical Associates|
|Santa Monica, California, United States, 90404|
|Principal Investigator:||Orrin M Troum, MD||Orrin M. Troum, MD & Medical Associates|